VTAMA Drug Patent Profile

When do Vtama patents expire, and when can generic versions of Vtama launch?

Vtama is a drug marketed by Dermavant Sci and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-three patent family members in thirty-six countries.

The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.

DrugPatentWatch^® Generic Entry Outlook for Vtama

Vtama will be eligible for patent challenges on May 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VTAMA

International Patents:	63
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	54
Patent Applications:	114
Drug Prices:	Drug price information for VTAMA
What excipients (inactive ingredients) are in VTAMA?	VTAMA excipients list
DailyMed Link:	VTAMA at DailyMed

See drug prices for VTAMA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VTAMA

NDA:

215272

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VTAMA

VTAMA is protected by four US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VTAMA

FDA Regulatory Exclusivity protecting VTAMA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes				Y
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Dermavant Sci	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes

International Patents for VTAMA

When does loss-of-exclusivity occur for VTAMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

European Patent Office

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VTAMA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3297605	COMPOSITIONS PHARMACEUTIQUES TOPIQUES (TOPICAL PHARMACEUTICAL COMPOSITIONS)
South Korea	20200087786	타피나로프의 제조 방법
Canada	2986251	COMPOSITIONS PHARMACEUTIQUES TOPIQUES (TOPICAL PHARMACEUTICAL COMPOSITIONS)
Taiwan	I705831
China	111511357	用于制备他品洛夫的方法 (PROCESS FOR PREPARING TAPINAROF)
Chile	2020001226	Proceso para preparar tapinarof.